scholarly journals SAT0054 Risk factors for acute exacerbation of rheumatoid arthritis-associated interstitial pneumonia

2017 ◽  
Author(s):  
A Yashima ◽  
H Yamashita ◽  
R Kamei ◽  
K Suga ◽  
M Nakano ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Acute Exacerbation ◽  
Interstitial Pneumonia

scholarly journals Acute exacerbation of interstitial pneumonia associated with rheumatoid arthritis during the course of treatment for Pneumocystis jirovecii pneumonia: a case report

2016 ◽  
Vol 9 (1) ◽  
Author(s):  
Takeshi Kuroda ◽  
Hiroyuki Takeuchi ◽  
Yukiko Nozawa ◽  
Hiroe Sato ◽  
Takeshi Nakatsue ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Acute Exacerbation ◽  
Interstitial Pneumonia ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia

scholarly journals Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Kodai Kawamura ◽  
Kazuya Ichikado ◽  
Hidenori Ichiyasu ◽  
Keisuke Anan ◽  
Yuko Yasuda ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Exacerbation ◽  
Interstitial Pneumonia ◽  
Real World ◽  
Antifibrotic Agents

scholarly journals Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 3979
Author(s):  
Satoshi Ikeda ◽  
Terufumi Kato ◽  
Hirotsugu Kenmotsu ◽  
Akimasa Sekine ◽  
Tomohisa Baba ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Acute Exacerbation ◽  
Interstitial Pneumonia ◽  
Patient Selection ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Great Promise ◽  
Small Cell Lung

Of patients with advanced non-small-cell lung cancer (NSCLC), 5–10% have interstitial pneumonia (IP) at the time of diagnosis. To avoid fatal acute exacerbations of pre-existing IP, appropriate patient selection and low-risk treatment choices are warranted. Risk factors for acute exacerbation of pre-existing IP with cytotoxic drugs include honeycomb lungs on computed tomography (CT) and low forced vital capacity, but risk factors with immune checkpoint inhibitors (ICIs) have not been fully investigated. For advanced or recurrent NSCLC with comorbid IP, carboplatin plus nanoparticle albumin-bound paclitaxel is the standard of care for first-line treatment, but second-line or later treatment has not been established. ICI holds great promise for long-term survival, but many challenges remain, including safety and appropriate patient selection. Since the indications for pharmacotherapy and radiotherapy for NSCLC with comorbid IP are quite limited, surgical resection should be considered as much as possible for patients with operable stages. A scoring system has been reported to predict the risk of postoperative acute exacerbation of pre-existing IP, but perioperative treatment has not been established. In the future, it is necessary to accumulate more cases and conduct further research, not only in Japan but also worldwide.

scholarly journals Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease

2015 ◽  
Vol 9s1 ◽  
pp. CCRPM.S23289 ◽  
Author(s):  
Takafumi Suda
Keyword(s):  
Rheumatoid Arthritis ◽  
Interstitial Lung Disease ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Acute Exacerbation ◽  
Interstitial Pneumonia ◽  
Usual Interstitial Pneumonia ◽  
Cytotoxic Agents ◽  
Radiological Patterns

Pulmonary involvement is common in rheumatoid arthritis (RA) and affects all the components of the lung. Interstitial lung disease (ILD) is the most predominant pulmonary manifestation and has been identified as the main cause of morbidity and mortality in RA. Clinically significant RA-ILD occurs in approximately 10% of RA patients. Several risk factors, such as old age, male gender, and smoking, have been reported to date. Histologically, the proportion of the usual interstitial pneumonia (UIP) pattern is higher in RA-ILD than in ILD associated with other connective tissue diseases, and RA-ILD also shows nonspecific interstitial pneumonia and organizing pneumonia patterns. High-resolution computed tomography scans are highly predictive of the histological UIP pattern with a specificity of 96%-100%. Acute exacerbation, which is the acute deterioration of the respiratory status characterized by newly developed bilateral infiltrates with unknown etiologies, has been reported in RA-ILD. Although acute exacerbation of RA-ILD has high mortality, similar to that of idiopathic pulmonary fibrosis, its incidence is lower in RA-ILD than in idiopathic pulmonary fibrosis. A consensus treatment has not yet been established. Current therapeutic regimens typically include corticosteroids with or without cytotoxic agents. Recent large longitudinal studies reported that the prognosis of RA-ILD was poor with a median survival of 2.6-3.0 years. Furthermore, histological and/or radiological patterns, such as UIP or non-UIP, have significant prognostic implications. RA-ILD patients with histological or radiological UIP patterns have poorer prognoses than those with non-UIP patterns. This review assessed the characteristics of RA-ILD by overviewing recent studies in the field and focused on the clinical significance of histological and/or radiological patterns in RA-ILD.

scholarly journals SAT0040 RISK FACTORS FOR DEVELOPING AND MORTALITY FOR ACUTE EXACERBATION OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 950.2-951
Author(s):  
S. Izuka ◽  
H. Yamashita ◽  
Y. Takahashi ◽  
H. Kaneko
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Interstitial Lung Disease ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Acute Exacerbation ◽  
Vascular Diseases ◽  
Collagen Vascular Diseases ◽  
Survivor Group

Background:Among collagen vascular diseases, rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is the most commonly associated with ILD with acute exacerbation (AE) [1]. One study reported that ILD diagnosis at an older age, the usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography, and methotrexate (MTX) use were associated with AE in patients with RA-ILD [2]. However, because these studies included few patients, the risk factors and prognosis of AE in patients with RA-ILD remain unclear. Therefore, this study examined the characteristics of RA-ILD patients with AE, and the variables associated with mortality due to AE of RA-ILD.Objectives:To investigate the risk factors for AE and mortality of RA-ILD.Methods:We retrospectively collected the clinical data of 165 RA-ILD patients admitted to our hospital between July 2010 and October 2019. We compared clinical characteristics between patients who developed AE (AE group) and those who did not (non-AE group), and identified the variables significantly associated with AE occurrence. We also compared the admission characteristics of those who survived (survivor group) and those who died (non-survivor group) after admission for AE. AE was defined using previously proposed criteria [3], which were modified slightly for application to RA-ILD.Results:The mean patient age was 73.6 ± 9.7 years and 97 (71.9%) patients were female. Thirty (22.2%) patients developed AE, of whom thirteen (43.3%) died (mean follow-up, 64.9 months). In univariate analyses UIP pattern and MTX were not associated with AE. However, in multivariate analyses, UIP pattern was associated with AE (OR 2.68, 95% CI 1.10–6.52,p=0.03). Median age (70vs. 80 years,p=0.003), non-use of MTX (70.6%vs. 23.1%,p=0.025), and C reactive protein level (median 9.38vs. 18.12 mg/dL,p=0.02) on admission were significantly higher in patients who died of AE. In the Cox proportional hazard model, UIP pattern (HR 4.67, 95% CI 1.02–21.5,p=0.048) and non-use of MTX (HR 0.16, 95% CI 0.04–0.72,p=0.016) were associated with death.Conclusion:Our data suggest that the UIP pattern is related to AE, and non-use of MTX and UIP pattern are related to death due to AE of RA-ILD.References:[1] Suda T, Kaida Y, Nakamura Y et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases.Respir Med2009;103:846-53.[2] Hozumi H, Nakamura Y, Johkoh T et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study.BMJ Open2013;3:e003132.[3] Collard HR, Moore BB, Flaherty KR et al. Idiopathic pulmonary fibrosis clinical research network investigators. Acute exacerbations of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2007;176:636-43.Disclosure of Interests:None declared

Risk factors for acute exacerbation of interstitial pneumonia after surgery with general anesthesia

2018 ◽  
Author(s):  
Keisuke Hosoki ◽  
Yu Mikami ◽  
Kunihiko Soma ◽  
Toshio Sakatani ◽  
Yukiyo Sakamoto ◽  
...  
Keyword(s):  
Risk Factors ◽  
General Anesthesia ◽  
Acute Exacerbation ◽  
Interstitial Pneumonia

scholarly journals Risk Factors for Postoperative Acute Exacerbation of Idiopathic Interstitial Pneumonia Following Surgery for Primary Lung Cancer

2014 ◽  
Vol 04 (02) ◽  
pp. 48-54
Author(s):  
Toru Tanaka ◽  
Shinji Abe ◽  
Hiroki Hayashi ◽  
Koichiro Kamio ◽  
Yoshinobu Saito ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Acute Exacerbation ◽  
Interstitial Pneumonia ◽  
Primary Lung Cancer ◽  
Idiopathic Interstitial Pneumonia

Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA

2010 ◽  
Vol 20 (3) ◽  
pp. 280-286 ◽  
Author(s):  
Kumi Shidara ◽  
Daisuke Hoshi ◽  
Eisuke Inoue ◽  
Toru Yamada ◽  
Ayako Nakajima ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Interstitial Pneumonia ◽  
Observational Cohort
Sign in / Sign up

Export Citation Format

Share Document